Translate Bio, Inc. Common Stock
TBIO
TBIO was delisted on the 13th of September, 2021.
77 hedge funds and large institutions have $421M invested in Translate Bio, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 30 increasing their positions, 12 reducing their positions, and 8 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 12
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
15% more funds holding
Funds holding: 67 → 77 (+10)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
19% less capital invested
Capital invested by funds: $521M → $421M (-$100M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.45M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.57M |
| 3 |
RI
RTW Investments
New York
|
+$1.44M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$673K |
| 5 |
State Street
Boston,
Massachusetts
|
+$529K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$7.65M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$3.96M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.86M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.7M |
| 5 |
HCM
Highbridge Capital Management
New York
|
-$1.65M |
TBIO Hedge Fund Activity: Q4 2019 in Review
77 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Translate Bio, Inc. Common Stock (TBIO) for Q4 2019, worth a combined $421M — down 19% from $521M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new TBIO positions and 8 closed out — a net gain of 10 holders — while 30 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $3.45M. The largest seller was Citigroup, cutting an estimated $7.65M.
- 77 institutional investors held Translate Bio, Inc. Common Stock (TBIO) as of Q4 2019, up from 67 in Q3 2019.
- Funds reported $421M of Translate Bio, Inc. Common Stock stock for Q4 2019, down 19% quarter-over-quarter.
- 18 funds opened new Translate Bio, Inc. Common Stock positions in Q4 2019 and 8 closed out, a net change of +10 holders.
- The largest Translate Bio, Inc. Common Stock buyer in Q4 2019 was BlackRock, an estimated $3.45M added.
- The largest Translate Bio, Inc. Common Stock seller in Q4 2019 was Citigroup, an estimated $7.65M sold.
Based on aggregated 13F filings for Q4 2019.